Prof Saul Faust, co-study leader at the University of Southampton and a consultant paediatrician, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”
Trending
- Is sustainable travel possible in times of mass tourism?
- Dance Theatre of Harlem: The ballet revolution hits Paris
- Brit Awards 2026: The surprise performers, tributes, and bits you might not have seen | Ents & Arts News
- Israel renews attacks on Iran: IDF announces more strikes on Tehran
- Strait of Hormuz halts after US‑Israel attack on Iran
- AI willing to ‘go nuclear’ in wargames, study finds – amid ‘stand-off’ between Pentagon and leading AI lab | US News
- Rescue centre sees rise in abandoned cat families
- Collagen supplements ‘may boost skin health’ but they’re not an ‘anti-wrinkle quick fix’, study suggests | Science, Climate & Tech News
